Side effects following administration of the Gam-COVID-Vac in Montenegro

Vera Dabanovic; Дабанович Вера

doi:10.15789/2220-7619-SEF-15628

Side effects following administration of the Gam-COVID-Vac in Montenegro

作者: Dabanovic V.¹
隶属关系:
1. Pharmacy Institution of Montenegro “Montefarm” Podgorica, Montenegro
期: 卷 13, 编号 6 (2023)
页面: 1150-1160
栏目: ORIGINAL ARTICLES
URL: https://journal-vniispk.ru/2220-7619/article/view/252314
DOI: https://doi.org/10.15789/2220-7619-SEF-15628
ID: 252314

如何引用文章

全文:

详细
全文:
作者简介
参考
补充文件
统计

详细

Introduction. In Montenegro, vaccination against COVID-19 infection began with the use of Gam-COVID-Vac, which was not approved for emergency use before the end of clinical trials, by the Food and Drug Administration and the European Medicines Agency. Therefore, it is necessary to emphasize the adverse effects.

Materials and methods. For the purpose of this study, there were collected data from national adverse events reporting form for Gam-COVID-Vac obtained from the Health Institution Pharmacy of Montenegro — Montefarm, as the holder of permits for these vaccines. Results. For the period March 1, 2021 to February 13, 2022, after administration of 16 756 doses of vaccine Gam-COVID, a total of 220 case reports, or 716 adverse effects were recorded. The mean age of vaccinated individuals who reported adverse effects was 40.79±11.35 years. Totally, 79.55% females versus 20.45% males reported side effects post-vaccination. The most common adverse reaction was pyrexia (79.55%). Other very common adverse effects were as follows: injection site pain (38.18%), headache (33.18%), myalgia (32.27%), malaise (31.82%), fever (30.45%), arthralgia (22.73%) as well as swelling and redness at the site of application (15.91%). Less common adverse effects were nausea, pain in extremity, diarrhea, dizziness, fatigue, sore throat and labial herpes. Serious adverse effects were recorded in 8 cases including tinnitus, thrombophlebitis, hypotension, chest pain, palpitations and peripheral cyanosis related to specific comorbidities.

Conclusions. After the administration of Gam-COVID vaccine, the population in Montenegro experienced mild to moderate adverse effects, with rare serious transient adverse effects related to specific comorbidities. The data presented here on investigating Gam-COVID-Vac caccine verified good safety profile and high tolerability evidenced by the statistics analysis as lacked COVID-19-associated hospitalizations or deaths.

关键词

COVID-19, vaccination, Gam-COVID-Vac, adverse effects, comorbidities, safety

全文:

##article.viewOnOriginalSite##

作者简介

Vera Dabanovic

Pharmacy Institution of Montenegro “Montefarm” Podgorica, Montenegro

编辑信件的主要联系方式.
Email: vera.dabanovic@montefarm.co.me

DSc (Medicine)

, Podgorica

参考

Adverse Events Following Immunization for COVID-19 Vaccines in Lebanon. COVID-19 Vaccines – Lebanon. URL: https://www.moph.gov.lb/userfiles/files/Quality%26Safety/PharmacovigilanceSystemInLebanon/Pharmacovigilance%20Report%20%23%204.pdf (18.08.2023)
Aghamirza Moghim Aliabadi H., Eivazzadeh-Keihan R., Beig Parikhani A., Fattahi Mehraban S., Maleki A., Fereshteh S., Bazaz M., Zolriasatein A., Bozorgnia B., Rahmati S., Saberi F., Yousefi Najafabadi Z., Damough S., Mohseni S., Salehzadeh H., Khakyzadeh V., Madanchi H., Kardar G.A., Zarrintaj P., Saeb M.R., Mozafari M. COVID-19: a systematic review and update on prevention, diagnosis, and treatment. MedComm. (2020), 2022, vol. 3, no. 1: e115. doi: 10.1002/mco2.115
Ahmed S.H., Waseem S., Shaikh T.G., Qadir N.A., Siddiqui S.A., Ullah I., Waris A., Yousaf Z. SARS-CoV-2 vaccine-associated-tinnitus: a review. Ann. Med. Surg. (Lond.), 2022, vol. 75: 103293. doi: 10.1016/j.amsu.2022.103293
Babamahmoodi F., Saeedi M., Alizadeh-Navaei R., Hedayatizadeh-Omran A., Mousavi S.A., Ovaise G., Kordi S., Akbari Z., Azordeh M., Ahangarkani F., Alikhani A. Side effects and immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran. Sci. Rep., 2021, vol. 11, no. 1: 21464. doi: 10.1038/s41598-021-00963-7
Bhatia M.S., Bhatia N.K., Bhatia N.K. Psychogenic lingual paresthesia. J. Clin. Diagn. Res., 2015, vol. 9, no. 5, pp. VD04–VD05. doi: 10.7860/JCDR/2015/11916.5897
Bok K., Sitar S., Graham B.S., Mascola J.R. Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity, 2021, vol. 54, no. 8, pp. 1636–1651. doi: 10.1016/j.immuni.2021.07.017
Chirico F., Teixeira da Silva J.A., Tsigaris P., Sharun K. Safety & effectiveness of COVID-19 vaccines: a narrative review. Indian. J. Med. Res., 2022, vol. 155, no. 1, pp. 91–104. doi: 10.4103/ijmr.IJMR_474_21
Conditional marketing authorization. European Medicines Agency. URL: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/conditional-marketing-authorisation (13.08.2023)
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol., 2020, vol. 5, no. 4, pp. 536–544. doi: 10.1038/s41564-020-0695-z
Emergency Use Authorization. Food and Drug Administration. URL: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization (13.08.2023)
Fiolet T., Kherabi Y., MacDonald C.J., Ghosn J., Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin. Microbiol. Infect., 2022, vol. 28, no. 2, pp. 202–221. doi: 10.1016/j.cmi.2021.10.005
Gupta A., Sardar P., Cash M.E., Milani R.V., Lavie C.J. Covid-19 vaccine-induced thrombosis and thrombocytopenia-a commentary on an important and practical clinical dilemma. Prog. Cardiovasc. Dis., 2021, vol. 67, pp. 105–107. doi: 10.1016/j.pcad.2021.05.001
Hsu C.J., Hung J.H., Lin I.H., Tseng S.H., Lin S.H., Huang Y.H. Overweight and obesity as risk factors for recurrent herpetic stromal keratitis during long-term antiviral prophylaxis. Viruses, 2022, vol. 14, no. 12: 2812. doi: 10.3390/v14122812
Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, vol. 395, no. 10223, pp. 497–506. doi: 10.1016/S0140-6736(20)30183-5
Karjala Z., Neal D., Rohrer J. Association between HSV1 seropositivity and obesity: data from the National Health and Nutritional Examination Survey, 2007–2008. PLoS One, 2011, vol. 6, no. 5: e19092. doi: 10.1371/journal.pone.0019092
Kovács L., Paprika D., Tákacs R., Kardos A., Várkonyi T.T., Lengyel C., Kovács A., Rudas L., Pokorny G. Cardiovascular autonomic dysfunction in primary Sjögren’s syndrome. Rheumatology (Oxford), 2004, vol. 43, no. 1, pp. 95–99. doi: 10.1093/rheumatology/keg468
Kovesdy C.P., Furth S.L., Zoccali C.; World Kidney Day Steering Committee. Obesity and kidney disease: hidden consequences of the epidemic. J. Nephrol., 2017, vol. 30, no. 1, pp. 1–10. doi: 10.1007/s40620-017-0377-y
Kyriakidis N.C., López-Cortés A., González E.V., Grimaldos A.B., Prado E.O. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines, 2021, vol. 6, no. 1: 28. doi: 10.1038/s41541-021-00292-w
Lamprinou M., Sachinidis A., Stamoula E., Vavilis T., Papazisis G. COVID-19 vaccines adverse events: potential molecular mechanisms. Immunol. Res., 2023, vol. 71, no. 3, pp. 356–372. doi: 10.1007/s12026-023-09357-5
Lisy M., Urban N., Brunner-Ziegler S., Weber B., Bauer W.M., Dassler E., Koppensteiner R., Handisurya A. Temporal association between COVID-19 vaccination and Raynaud’s phenomenon: a case series. Hum. Vaccin. Immunother., 2023, vol. 19, no. 1: 2199653. doi: 10.1080/21645515.2023.2199653
Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., Tukhvatulin A.I., Zubkova O.V., Dzharullaeva A.S., Kovyrshina A.V., Lubenets N.L., Grousova D.M., Erokhova A.S., Botikov A.G., Izhaeva F.M., Popova O., Ozharovskaya T.A., Esmagambetov I.B., Favorskaya I.A., Zrelkin D.I., Voronina D.V., Shcherbinin D.N., Semikhin A.S., Simakova Y.V., Tokarskaya E.A., Egorova D.A., Shmarov M.M., Nikitenko N.A., Gushchin V.A., Smolyarchuk E.A., Zyryanov S.K., Borisevich S.V., Naroditsky B.S., Gintsburg A.L.; Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet, 2021, vol. 397, no. 10275, pp. 671–681. doi: 10.1016/S0140-6736(21)00234-8
Mehrara B.J., Greene A.K. Lymphedema and obesity: is there a link? Plast. Reconstr. Surg., 2014, vol. 134, no. 1, pp. 154e–160e. doi: 10.1097/PRS.0000000000000268
Menni C., Klaser K., May A., Polidori L., Capdevila J., Louca P., Sudre C.H., Nguyen L.H., Drew D.A., Merino J., Hu C., Selvachandran S., Antonelli M., Murray B., Canas L.S., Molteni E., Graham M.S., Modat M., Joshi A.D., Mangino M., Hammers A., Goodman A.L., Chan A.T., Wolf J., Steves C.J., Valdes A.M., Ourselin S., Spector T.D. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect. Dis., 2021, vol. 21, no. 7, pp. 939–949. doi: 10.1016/S1473-3099(21)00224-3
Montalti M., Soldà G., Di Valerio Z., Salussolia A., Lenzi J., Forcellini M., Barvas E., Guttmann S., Messina R., Poluzzi E., Raschi E., Riccardi R., Fantini M.P., La Fauci G., Gori D.; San Marino Republic COVID ROCCA Group. ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance. EClinicalMedicine, 2021, vol. 38: 101027. doi: 10.1016/j.eclinm.2021.101027
Okawa Y., Ihara K. Sensorineural Hearing Loss in Sjögren’s Syndrome. Int. J. Mol. Sci., 2022, vol. 23, no. 19: 11181. doi: 10.3390/ijms231911181
Pagotto V., Ferloni A., Mercedes Soriano M., Díaz M., Braguinsky Golde N., González M.I., Asprea V., Staneloni M.I., Zingoni P., Vidal G., Aliperti V., Michelángelo H., Figar S. Active monitoring of early safety of Sputnik V vaccine in Buenos Aires, Argentina. Medicina (B. Aires), 2021, vol. 81, no. 3, pp. 408–414.
Parrino D., Frosolini A., Gallo C., De Siati R.D., Spinato G., de Filippis C. Tinnitus following COVID-19 vaccination: report of three cases. Int. J. Audiol., 2022, vol. 61, no. 6, pp. 526–529. doi: 10.1080/14992027.2021.1931969
Pravilnik o načinu prikupljanja podataka i prijavljivanja i pracenja neželjenih reakcija na lijekove za upotrebu u humanoj medicine. “Službeni list CG”, br. 56/11 i 6/13. 2015 December. URL: https://www.gov.me/dokumenta/9de59daf-b79f-4a4b-ab7a-7f305c3b7c2d (14.04.2023)
SPC Sputnik V (Gam-COVID vacc). URL: https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadSmPC/SMPCsputinikdr.Reddys.pdf (18.04.2023)
Takahashi J., Umehara T., Mitsumura H., Murakami H., Iguchi Y. Hyperadrenergic orthostatic hypotension with pure peripheral sympathetic denervation associated with Sjogren’s syndrome. Cureus, 2021, vol. 13, no. 9: e17805. doi: 10.7759/cureus.17805
Trougakos I.P., Terpos E., Alexopoulos H., Politou M., Paraskevis D., Scorilas A., Kastritis E., Andreakos E., Dimopoulos M.A. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. Trends Mol. Med., 2022, vol. 28, no. 7, pp. 542–554. doi: 10.1016/j.molmed.2022.04.007
Tseng P.T., Chen T.Y., Sun Y.S., Chen Y.W., Chen J.J. The reversible tinnitus and cochleopathy followed first-dose AstraZeneca COVID-19 vaccination. QJM, 2021, vol. 114, no. 9, pp. 663–664. doi: 10.1093/qjmed/hcab210
Worldometers. COVID-19 coronavirus pandemic. URL: https://www.worldometers.info/coronavirus/ (Accessed: 08.08.2023)
Zakon o ljekovima. “Službeni list Crne Gore”, br. 080/20 od 04.08.2020. URL: https://www.katalogpropisa.me/wp-content/uploads/2020/11/050-Zakon-o-ljekovima-Odlomak.pdf (16.08.2023)